ReviewFolia microbiologica2026
Gut microbiome-mediated bioactive ingredients and health benefits of medicinal and edible fermented products: A comprehensive review.
Review in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fermented foods and beverages represent dynamic biological ecosystems that integrate microbial communities, bioactive metabolites, and host interactions to promote health across nutritional, functional, and therapeutic domains. This comprehensive narrative review synthesizes current evidence on medicinal and edible fermented products, focusing on their bioactive generation, molecular mechanisms, and systemic health outcomes mediated by the gut microbiome. Fermentation processes, driven by lactic acid bacteria, yeasts, and mixed consortia, transform substrates into 31 key bioactives, including short-chain fatty acids (SCFAs), bioactive peptides, exopolysaccharides (EPS), and modified polyphenols. These compounds arise through microbial proteolysis, glycolysis, and biotransformation, enhancing bioavailability and functionality compared to unfermented counterparts. Mechanistically, bioactives strengthen gut barrier integrity via tight-junction upregulation and mucin production; modulate immunity through Toll-like receptor activation and T-cell differentiation; regulate metabolism by improving glucose/lipid profiles; and mitigate inflammation via NF-κB inhibition and Nrf2 activation. Gut microbiota-host crosstalk extends these effects systemically, influencing the gut-brain axis and extra-intestinal organs. Epidemiological and clinical data link regular consumption particularly of yogurt, kimchi, and kefir-to reduced risks of colorectal cancer (dose-response patterns), type 2 diabetes (8-15% HbA1c reductions), cardiovascular disease (5-10% cholesterol lowering), and enhanced immune resilience (20-35% fewer infections). Benefits also encompass gastrointestinal health (IBS symptom relief), neuroprotection (cognitive improvements), and cancer prevention. Despite promising findings, challenges persist in standardization, microbial viability during processing, and long-term human trials. Future directions emphasize multi-omics integration, AI-driven precision fermentation, and personalized interventions to validate fermented products as evidence-based therapeutics, bridging traditional practices with modern nutrition science.
Indexed as
Identifiers
42176172What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.